Literature DB >> 31169977

Mineralocorticoid antagonists and ENaC inhibitors in hyperaldosteronism.

Michael A Hill1, James R Sowers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31169977      PMCID： PMC8030310          DOI： 10.1111/jch.13566

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  17 in total

Review 1.  Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.

Authors:  Johann Bauersachs; Frédéric Jaisser; Robert Toto
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.

Authors:  Silvia Monticone; Fabrizio D'Ascenzo; Claudio Moretti; Tracy Ann Williams; Franco Veglio; Fiorenzo Gaita; Paolo Mulatero
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

Review 3.  Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness.

Authors:  Guanghong Jia; Annayya R Aroor; Michael A Hill; James R Sowers
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

Review 4.  Potential Role of Antihypertensive Medications in Preventing Excessive Arterial Stiffening.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

Review 5.  Vascular mineralocorticoid receptor and blood pressure regulation.

Authors:  Antoine Tarjus; Cristian Amador; Luis Michea; Frédéric Jaisser
Journal:  Curr Opin Pharmacol       Date:  2015-02-28       Impact factor: 5.547

6.  Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice.

Authors:  Vincent G DeMarco; Javad Habibi; Guanghong Jia; Annayya R Aroor; Francisco I Ramirez-Perez; Luis A Martinez-Lemus; Shawn B Bender; Mona Garro; Melvin R Hayden; Zhe Sun; Gerald A Meininger; Camila Manrique; Adam Whaley-Connell; James R Sowers
Journal:  Hypertension       Date:  2015-05-26       Impact factor: 10.190

7.  Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.

Authors:  Joseph L Izzo; Michael Hong; Tanveer Hussain; Peter J Osmond
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-06       Impact factor: 3.738

8.  Amiloride Improves Endothelial Function and Reduces Vascular Stiffness in Female Mice Fed a Western Diet.

Authors:  Luis A Martinez-Lemus; Annayya R Aroor; Francisco I Ramirez-Perez; Guanghong Jia; Javad Habibi; Vincent G DeMarco; Brady Barron; Adam Whaley-Connell; Ravi Nistala; James R Sowers
Journal:  Front Physiol       Date:  2017-06-30       Impact factor: 4.566

9.  Dendritic Cell Amiloride-Sensitive Channels Mediate Sodium-Induced Inflammation and Hypertension.

Authors:  Natalia R Barbaro; Jason D Foss; Dmytro O Kryshtal; Nikita Tsyba; Shivani Kumaresan; Liang Xiao; Raymond L Mernaugh; Hana A Itani; Roxana Loperena; Wei Chen; Sergey Dikalov; Jens M Titze; Bjorn C Knollmann; David G Harrison; Annet Kirabo
Journal:  Cell Rep       Date:  2017-10-24       Impact factor: 9.423

10.  Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.

Authors:  Amy McCurley; Paulo W Pires; Shawn B Bender; Mark Aronovitz; Michelle J Zhao; Daniel Metzger; Pierre Chambon; Michael A Hill; Anne M Dorrance; Michael E Mendelsohn; Iris Z Jaffe
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440
View more
  1 in total

Review 1.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.